Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Neuromodulation: Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

$4,750.00

This report provides an overview of primary neurological diseases/disorders treated with deep brain stimulation (DBS) and vagus nerve stimulation (VNS), as well as overviews of DBS and VNS neuromodulation technologies, competitors, sales, forecasts, and competitive and market analysis. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets.
May 26, 2022
Find out more
Key Trends in European Market Access

$2,995.00

This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.
January 26, 2016
Find out more
Afinitor
Read More
Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to S phase.
March 6, 2019
Find out more
Molecular Diagnostics

$4,750.00

Molecular diagnostics is being applied to an increasingly wide range of applications in infectious disease, oncology, and genetic disease diagnosis and screening, and to a number of emerging applications. The market for molecular diagnostics products totaled nearly $21bn in 2021. Following a projected downturn in 2022 and 2023 due to a decline in COVID-19 testing, the market is expected to return to growth in 2024. Drivers of the market will include adoption of new types of tests, expansion of target populations for molecular testing, and advances in the level of diagnostic testing services provided, particularly in developing countries.
June 28, 2022
Find out more
Yescarta
Read More
Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.
January 30, 2019
Find out more
Seizure Pulse Survey

$599.00

Eslicarbazepine has been approved in ex-US markets including the EU for years.

We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.
March 25, 2014
Find out more
Gilotrif
Read More
Gilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4.
August 30, 2018
Find out more
Pradaxa
Read More
Pradaxa (dabigatran; Boehringer Ingelheim) is an orally available direct thrombin inhibitor (factor IIa inhibitor) indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who previously received treatment with a parenteral anticoagulant for five to 10 days.
March 15, 2018
Find out more
Tykerb
Read More
Tykerb (lapatinib; Novartis) is an orally available EGFR (epidermal growth factor receptor) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor.
March 9, 2015
Find out more
Market Spotlight: Systemic Lupus Erythematosus (SLE)

$1,318.00

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 23, 2022
Find out more
Complera
Read More
Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson & Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Dyslipidemia KOL Insight Interview #2

$599.00

Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.
July 28, 2014
Find out more
Epidiolex
Read More
GW Pharmaceuticals is developing Epidiolex, a first-in-class cannabinoid drug for the treatment of

childhood seizures.
May 23, 2017
Find out more
TS-1
Read More
TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients.
December 11, 2017
Find out more
PDR001
Read More
PDR001 (Novartis) is a fully humanized monoclonal antibody designed to inhibit the negative immunoregulatory receptor programmed death-1 (PD-1). PDR001 blocks the interaction between PD-1 and its ligands, programmed death-ligand 1 (PD-L1) and PD-L2; the signaling elicited by this interaction inhibits T-cell activation.
May 23, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *